Currently Enrolling Trials
TAP Holdings received approval from the U.S. Food and Drug Administration (FDA) for PREVACID(R) (lansoprazole) Delayed-Release Capsules in the short-term treatment of Symptomatic GERD. The most common symptom of GERD is heartburn caused by the reflux of gastric juices from the stomach into the esophagus.
PREVACID is well tolerated. The most frequently reported adverse events included headache, abdominal pain and diarrhea.